The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer - In Reply

Research output: Contribution to journalLetter

Original languageEnglish
JournalJAMA oncology
DOIs
Publication statusPublished - Jan 1 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{f502c4fbfede4ebba468462dd205fa90,
title = "The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer - In Reply",
author = "Giacomo Bregni and Stefania Sciallero and Alberto Sobrero",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamaoncol.2019.2991",
language = "English",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",

}

TY - JOUR

T1 - The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer - In Reply

AU - Bregni, Giacomo

AU - Sciallero, Stefania

AU - Sobrero, Alberto

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85070899575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070899575&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.2991

DO - 10.1001/jamaoncol.2019.2991

M3 - Letter

AN - SCOPUS:85070899575

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

ER -